Nouvelle déclaration d'incident
No de la demande: 2012-2817
Numéro de référence du titulaire d'homologation: PROSAR Case #: 1-30600188
Nom du titulaire (nom légal complet, aucune abbréviation): Syngenta Canada Inc.
Adresse: 140 Research Lane, Research Park
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G4Z3
Incident chez l'humain
Pays: CANADA
État: ALBERTA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: Axial (nonspecific)
ARLA No d'homologation 28328 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Quilt (nonspecific)
Non
Inconnu
Professionnel de la santé
Sexe: Homme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Inconnu
Inconnu
Déversement de pesticide
Inconnu
Inconnu
Unknown / Inconnu
Unknown / Inconnu
1-30600188- The reporter, a health care professional, indicated a patient had been exposed to several herbicides. The reporter indicated the patient which was seen at her facility the day prior had been exposed to two registrant herbicides. The first contained the active ingredients azoxystrobin and propiconazole and the second pinoxaden. The product identification information given by the reporter was vague. She was unable to provide precise names and was unable to give registration numbers. She indicated, further, a third non-registrant product referred to as Libertymay also have been involved. The reporter stated she works in an emergency department (she did not clarify in what capacity) where the patient presented in the back of an ambulance. The adult male had spilled the products in the back of his truck earlier the same day, cleaned up while wearing cotton gloves, and then eaten food without first washing his hands. The reporter stated he had presented in respiratory distress and had been diagnosed with organophosphate poisoning. The reporter stated her primary motive for calling was occupational safety for the health care professionals who may work with the patient. The reporter described no additional exposure other than the primary patient. The reporter was advised none of the products described were organophosphates or known to be cholinesterase inhibitors. The caller was advised of proper precautions to take, and decontamination/treatment of the affected patient. The reporter was advised to investigate further as the diagnosis did not match the expectations of the products whose names were provided. On follow up three days later the reporter was unable to provide additional information other than to report that the patient had improved with a course of oral antibiotics. The symptoms described are not consistent with known effects of the registrants product(s). No further information is available.
Modérée